QUICK READ: Hydroxychloroquine does NOT prevent the Coronavirus and could be fatal to people who take it. There currently exists no definitive proof that the drug, often prescribed for rheumatoid arthritis, lupus and other autoimmune diseases, will aid patients fighting COVID-19. Many public health experts have been baffled by Trump’s stumping for hydroxychloroquine but baffled isn’t enough they need to call out his towering ignorance.
QUICK READ: Amarin lost a legal fight over its heart drug patent and shares tanked. Amarin shares fell sharply after a federal judge ruled that key patents covering its heart drug Vascepa were invalid. Should they have gambled?
QUICK READ: Scientists need to understand the common denominator that makes some people gravely ill versus some who just get mild symptoms when it comes to the Coronavirus.
QUICK READ: In a major development, a Japanese pharmaceutical company has started the final stages of human trial for its antiviral flu drug to treat COVID-19. But will their clinical trials meet the criteria for new drug approval for the FDA if successful?
QUICK READ: The pandemic is changing healthcare rapidly and along with that change is going to be new patient attitudes about choosing healthcare treatments.
QUICK READ: Because of the pandemic people are putting off annual physicals and going to see their doctor for health problems that could become worse. Sure telehealth can be of some help but technology can’t replace a person-to-person conversation with an HCP.
QUICK READ: The FDA and some drug companies are moving quickly to get approvals for the treatment of the Coronavirus. However, they could be moving too quickly. Science requires data and getting good data takes time. There are no quick miracles here and politics should not be part of the equation.
QUICK READ: Budgets for DTC and HCP marketing are going to get face huge cuts through the end of the year. In addition/ companies are deciding how to cut salesforce budgets. As one executive told me “this is going to be bad”.